Quantcast
Channel: Europe Headlines on One News Page [United Kingdom]
Viewing all 65275 articles
Browse latest View live

Global Blockchain Technology In Healthcare Market Will Reach USD 1415.59 Million By 2024: Zion Market Research

0
0
According to the report, global blockchain technology in healthcare market was valued at approximately USD 34.47 million in 2017 and is expected to generate revenue of around USD 1415.59 million by end of 2024, growing at a CAGR of around 70.45% between 2018 and 2024.

New York, NY, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled *“Blockchain Technology in Healthcare Market by Application (Clinical Data Exchange & Interoperability, Supply Chain Management, and Claims Settlement & Billing) and End User (Healthcare Payers, Pharmaceutical Companies, and Healthcare Providers): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024”*. According to the report, global blockchain technology in healthcare market was valued at approximately USD 34.47 million in 2017 and is expected to generate revenue of around USD 1415.59 million by end of 2024, growing at a CAGR of around 70.45% between 2018 and 2024.

Blockchain is a digital, public ledger of transactions comprising of a list of blocks (records) that can be viewed by everyone. Blockchain is a type of distributed ledger that uses nodes (independent computers) to document, share, and integrate transactions into their specific electronic ledgers. The data is organized into blocks that are tied up. Blockchain database is never stored in a single location; the data is accessible to everyone on the internet.

*Browse through 61 Tables & 17 Figures spread over 110 Pages and in-depth TOC on “Global Blockchain Technology in Healthcare Market Size, Share, Industry Applications and Forecast, 2017 - 2024”.*

*Request Free Sample Report of Global Blockchain Technology In Healthcare Market Report @* https://www.zionmarketresearch.com/sample/blockchain-technology-healthcare-market

The most important application of blockchain technology in healthcare is in the management of health data. The security and interoperability of health data can be improved exceptionally by using blockchain technology in healthcare. There is a growing demand for integrated healthcare services along with need for information technology based system to manage data. Blockchain technology can be a great solution to all these issues affecting the healthcare industry. Blockchain technology can decentralize the data storage and enable data sharing without any deterrence. The shared data can make it possible for doctors to access real-time information. The data from wearables can also be integrated into medical records using blockchain technology.

Blockchain technology also has applications in drug development. The technology can make patient data easily accessible and put brakes on counterfeit drug indications. Blockchain technology can also minimize the frauds related to claims and billing. In medical research, blockchain technology can help in integrating the results obtained through clinical trials. 

*Download Free Report PDF Brochure: *https://www.zionmarketresearch.com/requestbrochure/blockchain-technology-healthcare-market

The distributed blockchain was originally developed to act as a public transaction ledger of bitcoin. The initial work on cryptographically secured block chains was illustrated by W. Scott Stornetta and Stuart Haber in 1991. Their aim was to make it impossible to tamper with documents’ timestamps by executing an infallible system. Initially, blockchain technology was limited to manage bitcoin however as the concept behind blockchain technology became popular, people started exploring other applications of the technology. Post-2014, there was a sudden rise in investment to explore the application of blockchain technology in healthcare, transportation, insurance, supply chains, voting and many more.

Aspects like increasing cases of a medical data breach, growing number of fraudulent drugs and medicines, rising investment in blockchain technology startups working in healthcare sector will push the growth of global blockchain technology in healthcare market. Other factors like growing adoption of blockchain as a service (BaaS) solutions and government initiatives in implementing blockchain technology in healthcare are expected to drive the blockchain technology in healthcare market growth. The growing use of Internet of Things (IoT) in healthcare will act as a major opportunity for the companies working in the blockchain technology in healthcare market. However, factors like absence of pivotal entity and universal standards, paucity of awareness and knowledge of blockchain technology will restrain the growth of blockchain technology in healthcare market.

*Request Discount on This Report: *https://www.zionmarketresearch.com/requestdiscount/blockchain-technology-healthcare-market

The global blockchain technology in healthcare market has been segmented into the application, end user, and region. The application segment has been segmented into clinical data exchange & interoperability, supply chain management, and claims settlement & billing. Supply chain management segment holds the maximum share of the application segment. Based on the end user, blockchain technology in healthcare market has been segmented into healthcare payers, pharmaceutical companies, and healthcare providers.

North America represents developed regional market for blockchain technology in healthcare and is expected to see the rapid growth in the years to come. The U.S. is by far the leading blockchain technology in healthcare market by country in North America. The U.S. market is expected to grow at the highest CAGR during the forecast period. This growth is mainly due to the presence of key startups working on blockchain technology, presence of developed IT infrastructure, and high government funding. Furthermore, the ongoing research on implementation of Internet of Things (IoT) in healthcare will promote the growth of blockchain technology in healthcare market.

Browse the full *"Blockchain Technology in Healthcare Market by Application (Clinical Data Exchange & Interoperability, Supply Chain Management, and Claims Settlement & Billing) and End User (Healthcare Payers, Pharmaceutical Companies, and Healthcare Providers): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017 - 2024"* report at https://www.zionmarketresearch.com/report/blockchain-technology-healthcare-market

Europe was the second largest blockchain technology in healthcare market and is expected to show significant growth in the years to come. This growth is mainly due to rising medical research activity, growing awareness regarding use of IT in medical data management, and presence of developed healthcare infrastructure.

Asia Pacific will grow at the highest rate over the forecast period. In Asia, China, India, and Japan will continue to be the fastest growing markets in blockchain technology in healthcare. Growth in Asia Pacific market is expected to be driven by developing healthcare IT infrastructure and growing government spending on health data management.

*Inquire more about this report before purchase @ *https://www.zionmarketresearch.com/inquiry/blockchain-technology-healthcare-market

In the Middle East & Africa; African region will register medium growth due to lack of awareness. Latin America is another important regional market and is expected to experience medium growth over the forecast period. Thus, all the aforementioned parameters are expected to propel the market growth in this region.

Some of the key players in the blockchain technology in healthcare market include Microsoft, IBM, PokitDok, Guardtime, Gem, iSolve, Chronicled, Hashed Health, Factom, Patientory, Proof.Work, FarmaTrust, SimplyVital Health, Medicalchain, and Blockpharma, among others.

*Request customized copy of report @ *https://www.zionmarketresearch.com/custom/3252

*This report segments the global blockchain technology in healthcare market as follows:*

*Global Blockchain Technology in Healthcare Market: By Application*

· Clinical Data Exchange & Interoperability
· Supply Chain Management
· Claims Settlement & Billing

*Global Blockchain Technology in Healthcare Market: By End User*

· Healthcare Payers
· Pharmaceutical Companies
· Healthcare Providers

*Global Blockchain Technology in Healthcare Market: By Region*

· North America

· The U.S.

· Europe

· UK
· France
· Germany

· Asia Pacific

· China
· Japan
· India

· Latin America

· Brazil

· The Middle East and Africa

*Browse More Related Reports:*

· *Laboratory Information Systems (LIS) Market: *https://www.zionmarketresearch.com/report/laboratory-information-systems-market
· *Care Management Solutions Market:* https://www.zionmarketresearch.com/report/care-management-solutions-market
· *Healthcare IT Outsourcing Market: *https://www.zionmarketresearch.com/report/healthcare-it-outsourcing-market
· *Healthcare IT Consulting Market: *https://www.zionmarketresearch.com/report/healthcare-it-consulting-market
· *Digital Health Market:* https://www.zionmarketresearch.com/report/digital-health-market    

*About Us:*Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

*Follow Us LinkedIn: *https://www.linkedin.com/company/zion-market-research
*Follow Us Twitter: *https://twitter.com/zion_research

*Blog:* http://www.intenseresearch.com | http://www.mrsresearchgroup.com | http://www.marketresearchtrade.com | https://qyresearchgroup.com | http://marketnreports.com | https://zmrnewsjournal.us | http://www.e-marketresearch.com

*Contact Us:*

Joel John
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
*Email:* sales@zionmarketresearch.com

*Website:* https://www.zionmarketresearch.com

* Blog:* http://zmrblog.com Reported by GlobeNewswire 17 minutes ago.

Binswanger Named Exclusive Agent by Eliken Property Management for a 288,137 Sq. Ft. Industrial Building in Conway, Arkansas

0
0
DALLAS, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Binswanger has been named exclusive agent by Eliken Property Management, LLC to represent them with the marketing of their 288,137 sq. ft. industrial building on 124 acres.  The property is located at 1800 Sturgis Road in Conway, Arkansas.

Built in 1995, the modern, single-story facility is in excellent condition.  Key features include 7" and 8" reinforce concrete floors; insulated metal panel walls; built-up insulated metal roof; circular steel columns spaced 40' x 65', ceiling heights from 32' to 50'; metal halide lighting; all utilities; four 25' x 20' and eleven 9' x 12' grade level roll up doors; eight 8' x 10' dock-high doors equipped with levelers, seals, and lights; approximately 21,149 sq. ft. of two-story, modern, office space; paved and lighted parking for approximately 200 cars; and a 300' interior rail spur is located at the high bay area.  Service is provided by Union Pacific Railroad.

The property is located minutes from Interstate Highway 40 and State Highway 365.  It is five minutes to the Conway Regional Airport and approximately 30 minutes to Little Rock Adams International Airport.

Eliken is offering the property for lease to one client or possibly subdividing the property.  Additionally the sale of the property will be considered as well.  The property will be marketed to manufacturers of paper, plastics and rubber, nonmetallic minerals, primary metals, fabricated metals, machinery, household appliances, electrical equipment, motor vehicle body and trailer and other miscellaneous manufacturers as well as prospects in mining, wholesale trade and retail trade industries.

Headquartered in Philadelphia, Pennsylvania, Binswanger is an international full-service real estate organization with offices worldwide throughout the United States, Canada, Latin America, Europe, the Middle East, and Asia. 

*CONTACT:
*Laurie Goldstein
215-448-6014
lgoldstein@binswanger.com

Holmes Davis
972-663-9494
hdavis@binswanger.com Reported by GlobeNewswire 7 minutes ago.

Advantage Solutions Acquires Jun Group to Help Accelerate Performance Outcomes for Both Brand and Retail Clients

0
0
Acquisition bolsters Advantage’s MomentAware geo-location data product, which helps define and predict when and where people shop, and drive conversions.

IRVINE, Calif., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Advantage Solutions (Advantage) announced today its acquisition of Jun Group, an industry-leading mobile video advertising company. Jun Group’s mobile software platform will enable Advantage to help clients access and advertise to tens of millions of consumers in brand-safe environments. Terms of the transaction were not disclosed.Jun Group’s mobile technology reaches consumers where they increasingly spend their time: in mobile applications. The company creates custom audience segments from opt-in poll questions. It then delivers beautiful, full-screen digital ads on smartphones, tablets, and laptops/desktops.

Advantage has been steadily building its own advanced shopper marketing audience product, known as MomentAware, which uses real-time geo-location data to help brands and retailers scale consumer engagement and deliver results to the bottom line. Adding Jun Group’s platform into the mix now enables the company to deliver tailored messaging across screens to customers who are most likely to take action.

“Jun Group’s mobile technology enhances our ability to reach the right people, at the right times, with the right messages,” said Jill Griffin, President of Advantage Marketing Partners. “This partnership instantly places Advantage at the forefront of multi-channel, holistic marketing that’s based on consumer preference and personal interest.”

Clients of both companies will enjoy the benefits of truly consumer-centric advertising that’s both highly targeted and works seamlessly across channels.

“How and where someone finds your message is as important as the message itself,” said Jun Group CEO Mitchell Reichgut. “We consistently outperform the industry by finding the right people and putting them in control of the ad experience. Together with Advantage we’ll extend this concept into a true, 360-degree marketing platform that delivers exceptional value for advertisers, and for their customers across multiple channels and locations.”

Jun Group was advised on the transaction by investment bank Petsky Prunier.

*ABOUT ADVANTAGE SOLUTIONS*
Advantage is a leading provider of technology-enabled sales and marketing business solutions designed to help manufacturers and retailers across a broad range of channels drive consumer demand, increase sales, and achieve operating efficiencies. The company’s marketing division, Advantage Marketing Partners, provides a broad spectrum of marketing capabilities and services across digital, experiential, traditional and shopper marketing. Advantage Marketing Partners is one of the fastest growing marketing organizations with a global ranking as the 6^th largest agency in North America and the 16^th largest worldwide. Advantage has offices throughout the United States, Canada, and Europe. For additional information, visit advantagesolutions.net.

*ABOUT JUN GROUP
*The word “Jun” means truth, and the company was built on the principles of honesty and transparency. Jun Group’s advertising technology enables millions of people to watch videos and visit the web pages of Fortune 500 brands on mobile devices, tablets, and laptops/desktops. Jun Group targets with great specificity in any geographic area across the US. The world’s best-known brands trust Jun Group to connect them with their customers because everything Jun Group does is viewable, brand-safe, and transparent.

Jun Group is based in New York, with offices in Chicago, Seattle, and Greater Los Angeles. Please visit http://www.jungroup.com or follow on Twitter @jungroup or LinkedIn for more information. press@jungroup.com

Will Minton
Advantage Solutions
will.minton@advantagesolutions.net

Adam Cohen Aslatei
Jun Group
acohen@jungroup.com Reported by GlobeNewswire 7 minutes ago.

Turkey boycotts human rights meeting over presence of NGOs

0
0
WARSAW, Poland (AP) — Turkey’s government is not attending Europe’s largest human rights conference because it was not allowed to prevent the participation of non-governmental organizations. The U.S. Helsinki Commission, a U.S. government agency, said on Twitter on Monday that “Turkey is the only country boycotting … because it insists on having the ability to […] Reported by Seattle Times 58 minutes ago.

Bankers downplay Brexit impact on London’s hub status

0
0
LONDON (AP) — Leading bankers have sought to downplay the immediate impact of Brexit on London’s position as the hub of the financial services industry in Europe. James Bardrick, the head of Citi UK and CEO of Citigroup Global Markets, told lawmakers Tuesday on the Treasury Select Committee that London will remain the group’s regional […] Reported by Seattle Times 58 minutes ago.

Bankers downplay Brexit impact on London's hub status

0
0
LONDON (AP) — Leading bankers have sought to downplay the immediate impact of Brexit on London's position as the hub of the financial services industry in Europe.James Bardrick, the head of Citi UK and CEO of Citigroup Global Markets,... Reported by New Zealand Herald 1 hour ago.

INVESTMENT IN ENVIRONMENTAL COMPLIANCE FOR MEDITERRANEAN ROUTE NETWORK

0
0
*COMPANY ANNOUNCEMENT*
 

*investment in environmental*
* compliance for Mediterranean route network*

DFDS will in 2019 invest DKK 300m to install scrubbers on 12 freight ferries deployed on freight routes in the Mediterranean between Turkey, Italy, Greece and France. The investment will ensure compliance with the new global rules that from 2020 aims to reduce sulphur emissions through limiting sulphur content in marine fuel oil to 0.5% or through other means, such as scrubbers, with at least a similar environmental effect.

The investment decision is based on the scrubber strategy that was applied in 2015 for the transition to the 0.1% sulphur content limit for DFDS' ferry route network in northern Europe. This strategy has proven to be a success from both an environmental, operational and business perspective.

"We are happy to already now start preparing for complying with the new limit on sulphur content in emissions in the Mediterranean. This will bring environmental benefits for all. By applying DFDS' extensive experience of procuring, installing and operating scrubber systems we are achieving both operational and financial synergies," says Niels Smedegaard, CEO of DFDS.

In line with DFDS' CSR policy and to comply with IMO's (International Maritime Organisation) upcoming regulation, hybrid scrubbers were chosen as the optimal solution for the fleet in the Mediterranean. The use of scrubbers will bring health and environmental benefits, particularly for people living close to ports and coastlines.

The 12 scrubbers will be supplied by ME Production, a Danish developer and manufacturer of customised emission reduction systems for marine applications, that DFDS has cooperated with previously.

*Contact*
Niels Smedegaard, CEO +45 33 42 34 00
Torben Carlsen, CFO +45 33 42 32 01
Søren Brøndholt Nielsen, IR +45 33 42 33 59
Gert Jacobsen, Communications +45 33 42 32 97This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.*Attachment*

· UK_Scrubbers_no_51_09_2018.pdf Reported by GlobeNewswire 1 hour ago.

5 Capital Cities Where a Couple Can Retire on less than $37,000 a Year—Internationalliving.com

0
0
An increasing number of Americans are retiring overseas to capital cities that offer a culture-rich lifestyle, excellent infrastructure, and top-class dining and entertainment, all at an affordable price tag. A new report from the editors at Internationalliving.com reveals five capital cities where a couple can retire on less than $37,000 a year—in Europe, Latin America, and Southeast Asia.

BALTIMORE (PRWEB) September 11, 2018

“An urban retirement holds increasing appeal for Baby Boomers keen on the idea of staying active and aging in place. In big cities like Washington D.C., retirees can easily access theater, dance, museums, restaurants, doctors, and grocery stores without getting in a car,” says Jennifer Stevens, Executive Editor of International Living. “But all that comes with a high price tag—especially for living and housing costs. The median household income in D.C. is $72,935, but experts say you need more like $90,811 to live there comfortably as a working person.

“As a retiree, if you figure 70% of that working income would suffice, that equates to $63,567.70 a year, or $5,297.30 per month, for a couple to retire comfortably in our nation’s capital.

“But retirees can gain all the same benefits of a cosmopolitan, urban lifestyle in the best-value capital cities overseas—for a small fraction of that price tag.”

The International Living report lists five capital cities in Europe, Latin America, and Southeast Asia where a retired couple can live well on less than $37,000 a year.

Panama City, Panama

Panama offers a very comfortable retirement solution, in part because the nation is much more developed than most visitors expect. Many are surprised by the modernity of Panama and the clusters of skyscrapers that define Panama City’s skyline—all of the amenities one could wish for are readily available.

Cosmopolitan Panama City is a true First World city in Central America. High-speed Internet and cell coverage are commonplace and the quality of air, water, and power is excellent.

Panama uses the U.S. dollar as its currency, making it especially convenient for expats from the States. There are also many English speakers in Panama, especially among the well-trained medical community. Tocumen International Airport is a regional hub and makes it easy to fly from Panama to nearly anywhere in the world, often with no layovers.

Panama City has a remarkable number of restaurants, park areas, water fronts, and a UNESCO World Heritage historic district. A couple can live a comfortable retirement, in a rented two-bedroom apartment in a central area, for $21,180 a year (which comes to $1,765 a month). Opting for more luxurious digs, a budget of $34,680 a year ($2,890 a month) would bankroll a lifestyle lacking nothing.

Phnom Penh, Cambodia.

Once famed as the “Pearl of Asia,” the Cambodian capital, Phnom Penh, has lots to offer expats—a stunningly low cost of living, bustling markets, and a thriving food scene, set to a backdrop of colonial French architecture and temples.

Attracted by its beauty, the warm and welcoming nature of its people, and its supreme affordability, retirees living in Phnom Penh can afford indulgences out of reach at home, including staff like a house keeper or gardener.

For golfers, it’s a wonderful place to have fun without breaking the bank. Not only is the weather great for a round of golf throughout the year, but the idyllic settings and lower prices make it a hole in one for keen golfers on the interesting and ambitiously designed courses.

A retired couple could enjoy a good life here on $1,838 a month, or just $22,050 a year.

Hanoi, Vietnam.

Hanoi, Vietnam’s capital city, is known for its French colonial architecture and rich culture with Southeast Asian, Chinese, and French influences. A beautiful place of parks and lakes, Hanoi has maintained its traditional charm while becoming a vibrant, modern city.

It’s a delightfully livable city—for every glitzy mall, there’s an incense-filled temple nearby and cultural influences of the past are still part of the modern-day fabric, from revered Confucian monuments to trendy French restaurants. For lovers of the four seasons, Hanoi’s hot summers, chilly winters, and near-perfect spring and fall weather are an added benefit.

This burgeoning, bustling city is the political hub of the country, as well as the cultural and historical center.

Hanoi has one of the lowest costs of living of any major city in Southeast Asia. A couple can live a comfortable lifestyle in Hanoi on a budget of $905 per month—$10,860 a year.

Lisbon, Portugal.

Portugal, the westernmost country on mainland Europe’s Iberian Peninsula, is a rising star on the European retirement map. Its capital, Lisbon—home to half a million people—is a gracious city, a place where you can enjoy a European lifestyle with history, romance, astonishing hospitality, and a seaside location to boot.

In this Old World haven, cable cars clatter over hilly, cobblestoned streets sweeping down to a sheltered bay. Lisbon’s climate is mild, even in the depths of an often-rainy winter, average lows are barely below 50 F, while summers are gloriously sunny and generally in the 70s F.

With all the amenities of a capital at hand—museums and performance spaces, restaurants and nightlife, an international airport—Lisbon is also one of the most affordable capitals in Western Europe. A couple could live well here for $3,065 a month—$36,780 a year—or on considerably less a little outside of the beautiful city center.

Quito, Ecuador.

Located high in the Andes mountains at 9,350 feet, Quito is one of the highest capital cities in the world. It is also one of the most dramatically situated, hemmed in by encircling peaks and volcanoes.

Today’s Quito is a world-class metropolis with happy surprises tucked into many corners—like an international airport that’s just a few years old. It’s also a nature lover’s delight with easy access to waterfalls, beaches, the Amazon jungle, and mountains just a few hours away.

The core of Ecuador’s capital is a UNESCO World Heritage Site packed with historical testaments to its rich colonial past. Narrow cobbled streets open into huge plazas dominated by domed churches and palatial buildings.

From museums to architecture, and art to theater, it has everything you would expect to find in any big city. And the cost of living in Quito is just a fraction of what it costs to live in North America. A monthly budget for a couple in Quito would run from $1,650 to $1,825—a yearly total of $19,800 to $21,900.

The full report can be found here: 5 Capital Cities Where a Couple Can Retire on Less Than $37,000 a Year

Editor's Note: Members of the media have permission to republish the article linked above once credit is given to Internationalliving.com
Further information, as well as interviews with expert authors for radio, TV or print, is available on request. Photos are also available.

For information about InternationalLiving.com content republishing, source material or to book an interview with one of our experts, contact PR Managing Editor, Marita Kelly, +001 667 312 3532, mkelly@internationalliving.com
Twitter: @inliving
Facebook: https://www.facebook.com/International.Living/

About International Living

Since 1979, Internationaliving.com has been the leading authority for anyone looking for global retirement or relocation opportunities. Through its monthly magazine and related e-letters, extensive website, podcasts, online bookstore, and events held around the world, InternationalLiving.com provides information and services to help its readers live better, travel farther, have more fun, save more money, and find better business opportunities when they expand their world beyond their own shores. InternationalLiving.com has more than 200 correspondents traveling the globe, investigating the best opportunities for travel, retirement, real estate, and investment. Reported by PRWeb 1 hour ago.

Global Carotenoids Market 2017-2018 & 2024: Market Projected to Surpass $2 Billion

0
0
Dublin, Sept. 11, 2018 (GLOBE NEWSWIRE) -- The "Global Carotenoids Market - Products and Applications" report has been added to *ResearchAndMarkets.com's* offering.Global demand for carotenoids by product is led by astaxanthin, estimated to account for about 32% in 2017, which is further projected to reach US$772 million by 2024. Carotenoids worldwide market is anticipated to touch US$1.5 billion in 2018.

Animal feed and food & beverage sectors are currently the largest markets for carotenoids globally. Carotenoids are used on a large scale in animal feeds, which is acting as the key growth driver of this market due to their high nutritive value and the pigmentation, which increases the palatability of the feed, in addition to enhancing the appearance of meat, meat products and fish.Growing awareness among consumers about benefits of carotenoids, greater emphasis on a healthy lifestyle and rising incidences of various diseases across the globe is driving the demand for carotenoids in dietary supplements and cosmetic industries.

*Research Findings & Coverage*

· Global Carotenoids market is analyzed in this report with respect to key product types and major applications
· The study exclusively analyzes the market of each product type and applications of Carotenoids by a major geographic region/country
· Intake of High Dietary Carotenoids Reduces the Risk of Advanced AMD
· Lutein and Zeaxanthin Isomers Beneficial in Ameliorating Effects of Blue Light Exposure
· Alpha Carotene Plays Critical Role in Metabolic Health
· Carotenoids to Harvest Solar Energy by Absorbing Blue/Green Lights
· Key business trends focusing on product innovations/developments, M&As, JVs and other recent industry developments
· Major companies profiled - 55
· The industry guide includes the contact details for 306 companies

*Key Topics Covered:**PART A: GLOBAL MARKET PERSPECTIVE*

*1. INTRODUCTION*
1.1 Product Outline
1.1.1 Carotenoid Structure
1.1.2 Nomenclature
1.1.3 Physical and Chemical Properties
1.1.3.1 Size and Shape
1.1.3.2 Solubility
1.1.3.3 Light Absorption and Color
1.1.4 Functions of Carotenoids
1.1.5 Carotenoids Antioxidant Properties
1.1.6 Interaction with Other Antioxidants
1.1.7 Sources of Carotenoids
1.1.7.1 Synthetic Sources
1.1.7.2 Natural Sources
1.1.7.2.1 Microbial Sources of Carotenoids
1.1.8 Classification of Carotenoids
1.1.8.1 Carotenes
1.1.8.1.1 Types of Carotenes
1.1.8.1.1.1 Lycopene
1.1.8.1.1.2 ?eta-Carotene
1.1.8.1.1.3 Beta-Carotene
1.1.8.2 Xanthophylls
1.1.8.2.1 Types of Xanthophylls
1.1.8.2.1.1 Astaxanthin
1.1.8.2.1.2 Canthaxanthin
1.1.8.2.1.3 Capsanthin
1.1.8.2.1.4 Fucoxanthin
1.1.8.2.1.5 Lutein
1.1.8.2.1.6 Violaxanthin
1.1.8.2.1.7 Zeaxanthin
1.1.8.2.1.8 Beta-Cryptoxanthin
1.1.8.3 Apocarotenoids
1.1.8.3.1 Annatto

*2. CAROTENOIDS APPLICATIONS - A MARKET SNAPSHOT*
2.1 Food & Beverages
2.2 Cosmetics
2.3 Dietary Supplement
2.4 Animal Feed
2.5 Pharmaceuticals

*3. KEY MARKET TRENDS*
3.1 Intake of High Dietary Carotenoids Reduces the Risk of Advanced AMD
3.2 Protective Effect of Serum Carotenoid Concentrations on Diabetes Mellitus and Diabetes Retinopathy
3.3 Lutein and Zeaxanthin Isomers Beneficial In Ameliorating Effects of Blue Light Exposure
3.4 Dietary Carotenoids and Vitamin C Inversely Correlate To Risk of Lung Cancer
3.5 Alpha Carotene Plays Critical Role in Metabolic Health
3.6 The Effective Role of Beta-Cryptoxanthin in Obesity and Metabolic Syndrome
3.7 Extraction of Carotenoids from Microalgae and Seaweeds Using Innovative Technologies
3.8 Carotenoids to Harvest Solar Energy by Absorbing Blue/Green Lights

*4. KEY GLOBAL PLAYERS*

· Algatechnologies Ltd. (Israel)
· Allied Biotech Corporation (Taiwan)
· BASF SE (Germany)
· Beijing Gingko Group (BGG) (China)
· CHR. Hansen Holding A/S (Denmark)
· Cyanotech Corporation (United States)
· D.D. Williamson & Co., Inc. (United States)
· Divis Laboratories Limited (India)
· Doehler GmbH (Germany)
· E.I.D Parry (India) Ltd. (India)
· Fuji Chemical Industry Co., Ltd. (Astareal) (Japan)
· Guangzhou Leader Bio-Technology Co., Ltd. (China)
· Kemin Industries, Inc. (United States)
· Lycored Ltd. (Israel)
· Naturex SA (France)
· Novus International, Inc (United States)
· Royal DSM NV (The Netherlands)
· Zhejiang Medicine Co., Ltd. (China)
· Zhejiang NHU Co., Ltd. (China)

*5. KEY BUSINESS AND PRODUCT TRENDS*

· Nutrex Hawaii Receives USP Verified Mark for BioAstin Hawaiian Astaxanthin Products
· Israeli biotech startup, NextFerm Technologies, to commercialize Phaffia based Astaxanthin
· Chr. Hansen to Upgrade Main Colors Research Facility and Global Expertise Center
· Algatech Launches Fucovital, 3% Fucoxanthin Oleoresin Extracted From Microalgae
· BGG and SolixAlgredients Merged their Algae Ingredients Operations
· Algatechnologies Invests in New Zealand based Astaxanthin Producer Supreme Health
· AstaReal's Natural Astaxanthin for Sports Nutrition Market Exhibited at Vitafoods Europe 2018
· Algatech and Sphera Join Forces to Develop Innovative Functional Ingredient Formats
· Algalif Expands into Asia-Pacific Market and Introduces Astaxanthin Finished Products
· AlgaeHealth'sAstaZine Natural Astaxanthin Tested 100% Glyphosate-Free to Extreme Level of Detection
· Sensient Technologies to Acquire GlobeNatural's Natural Color Business
· Nutrex Hawaii's BioAstin Hawaiian Astaxanthin and MD Formulas Verified by IGEN
· DDW Launches EmulsiTech Cloudy Paprika for Orange Beverages
· Cardax and HECL Form ZanthoSyn Distribution Pact for China
· KnipBio Meal, Premium Aquafeed Ingredient Developed by KnipBio
· Non-GMO Accreditation for Algalif'sAstalf 5% and 10% Oleoresin Products
· Novus Launches COLORTEK Yellow, a Natural Pigment Technology
· NOW Foods Formed Astaxanthin Distribution Pact with AlgaeHealth
· Felcra and Algatech International Partner on Commercial Production of Algae
· Chr. Hansen Introduces New Line of Yellow And Orange Beverage Colors
· Algatech'sAstaPure Natural Astaxanthin Verified by the Non-GMO Project
· Two New US Patents Granted to Valensa
· Chr. Hansen Enters Into Distribution Agreement with Cornelius
· Lycored Launches Lycopene Lycopedia, a Digital Encyclopedia
· Algatechnologies Starts Marketing its AstaPure Astaxanthin in Brazil
· Cyanotech'sBioAstin SCE 5 and Vegan BioAstin Soft Gels are Now Halal Certified
· NHFPC Approval for ZeaONE Provides a New Opportunity for Vision Benefits
· Valensa International Awarded US Patent for EyePro MD Formula
· NIH Chose Cardax's Astaxanthin Compound for Anti-Aging Interventions Testing Program
· Subitec Builds New Astaxanthin Production Facility for Algamo
· MBD Energy to Complete the Construction of Australia's First Astaxanthin Plant
· US FDA Granted Approval for Parry Nutraceuticals' Indian Microalgae Facility
· Algatech'sAstaPure Natural Astaxanthin Received NOP Certification from the USDA Agricultural Marketing Service
· Algalif Receives EU Novel Food Certification for its Natural Astaxanthin
· Lycored&Algatechnologies Team Up To Launch Astaxanthin Beadlets
· California GOLD Nutrition Astaxanthin Supplement Caps with TruAzta Label now Available on iHerb
· Vegan and Vegetarian Certifications Granted for Heliae Astaxanthin Products
· Algalif Introduces its Astalif Astaxanthin at Vitafoods Europe 2017
· Launch of Algatechnologies' Whole-Algae AstaPure Natural Astaxanthin at Vitafoods 2017
· AstaReal, the First and Only Preferred Supplier of Natural Astaxanthin Recognized by NASC
· Algaetech Targets a Daily Sale of 500,000 Astaxanthin Eggs in the Next 24 Months
· Kemin Industries Opens New Manufacturing Unit in Russia for Feed Ingredients
· BASF Unveils Lucarotin 10 CWD/O Plus Orange Colorant
· Farbest Brands Collaborated WithColorMaker to Offer a Line Of 100% Natural Colors
· Both FDA GRAS and EU Novel Food Certifications for INNOBIO's Astaxanthin
· Food Safety Authority of Ireland Approved AstaZine Natural Astaxanthin as a Novel Food
· Heliae's Joint Venture, Alvita Starts Astaxanthin Operations in Japan
· New NDI Notification Submitted by AlgaeHealth for Use of AstaZine at a Daily Dose of Over 12mg
· NSF International Granted GMP Registration to AstaReal USA
· Mitsubishi Corporation Subsidiary MC Biotech Opens Astaxanthin Production Facility in Brunei
· Canadian Astaxanthin Producer, Regenurex Health Corporation's Astaxanthin is rebranded as Regenurex, replacing AstaVantage
· Cyanotech'sBioAstin SCE Products are Now Non-GMO Project Verified
· Astavita Develops a New Astaxanthin Formulation AstaMed MYO for Clinical Dietary Management of Sarcopenia
· Cardax Introduces ZanthoSyn Synthetic Astaxanthin Supplement
· Launch of Valensa's Flex Pro ES Chewables
· Algae Health Sciences, Inc is the New Name for BGG's Algae Subsidiary
· Kemin Receives US Blue Light Protection Patent for FloraGLO
· DDW Rolls Out Novel Natural Colorant Made From Purple Corn
· BGG received a Notice of Trademark Infringement from ArcticFarma
· Astarism for Skin Conditioning Introduced by Astavita
· DDW Introduces New Yellow and Orange Clear Liquid Emulsions
· SolixAlgredients Gets UL Registrar Certification for Solasta Astaxanthin
· Commercial Launch of Astatude Astaxanthin by Algaetech International
· Algaetech to Build its Second Astaxanthin Production Facility in Brunei
· BGG to Broaden its Product Offering in Mexico
· AstaReal Technologies Inc Merged into AstaReal Inc
· AlgaeHealth'sAstaZine Natural Astaxanthin gets FDA NDI Notification
· Fuji Chemical Receives Halal and Kosher Certifications
· AlgaeHealth's Astaxanthin Crop is Now Organic Certified
· ANVISA Approved Kemin'sZeaONE Zeaxanthin for Sale in Brazil
· AstaSuper Natural Astaxanthin Feed Product Launched by Fenchem
· Opening of BGG's Third Affiliate in Switzerland
· AstaReal Natural Astaxanthin is now Non-GMO Project Verified
· Frutarom and Algalo Industries Collaborate to Build a Modern Biotechnology Facility
· DDW Acquires KleurCraft Food Colorings Portfolio from SVZ International
· DSM And Kemin Introduces New Forms of Lutein and Zeaxanthin
· DSM Canthaxanthin Supplement Received GRAS by FDA

*6. GLOBAL MARKET OVERVIEW*
6.1 Global Carotenoids Market Overview by Product Type
6.1.1 Carotenoids Product Type Market Overview by Global Region
6.1.1.1 Astaxanthin
6.1.1.2 Canthaxanthin
6.1.1.3 Beta-Carotene
6.1.1.4 Lutein
6.1.1.5 Lycopene
6.1.1.6 Annatto
6.1.1.7 Other Carotenoids
6.2 Global Carotenoids Market Overview by Application
6.2.1 Carotenoids Application Market Overview by Global Region
6.2.1.1 Food & Beverages
6.2.1.2 Cosmetics
6.2.1.3 Dietary Supplements
6.2.1.4 Animal Feed
6.2.1.5 Pharmaceuticals

*PART B: REGIONAL MARKET PERSPECTIVE*

*REGIONAL MARKET OVERVIEW*

*7. NORTH AMERICA*Major Market Players

· Algae Health Sciences, Inc. (United States)
· Algae to Omega Holdings Inc (United States)
· Astareal, Inc. (United States)
· Cyanotech Corporation (United States)
· D.D. Williamson & Co., Inc. (United States)
· Farbest Brands (United States)
· Garden State Bioenterprises LLC (GS BIOE) (United States)
· Heliae Development LLC (United States)
· Kemin Industries, Inc. (United States)
· Novus International, Inc (United States)
· Piveg, Inc. (United States)
· Regenurex Health Corporation (Formerly AlgaeCan Biotech) (Canada)
· Sensient Technologies Corporation (United States)
· Solix Algredients, Inc. (United States)
· Valensa International (U. S. Nutraceuticals LLC) (United States)

*8. EUROPE*Major Market Players

· Algalif Iceland EHF (Iceland)
· Algamo Ltd. (Czech Republic)
· Astareal AB (Sweden)
· BASF SE (Germany)
· CHR. Hansen Holding A/S (Denmark)
· Doehler GmbH (Germany)
· Naturex SA (France)
· Royal DSM NV (The Netherlands)*9. ASIA-PACIFIC*Major Market Players

· Algaetech International Sdn Bhd (Malaysia)
· Allied Biotech Corporation (Taiwan)
· Alvita Corporation (Japan)
· Astamaz NZ Ltd (New Zealand)
· Beijing Gingko Group (BGG) (China)
· Biogenic Co., Ltd. (Japan)
· Divis Laboratories Limited (India)
· E.I.D Parry (India) Ltd. (India)
· Ennature Biopharma - India Glycols Limited (India)
· Excelvite Sdn. Bhd (Malaysia)
· Fenchem Biotek Ltd. (China)
· Fuji Chemical Industry Co., Ltd. (Astareal) (Japan)
· Guangzhou Leader Bio-Technology Co., Ltd. (China)
· Inner Mongolia Ever Brilliance Biotechnology Co., Ltd. (KEB) (China)
· Innobio Ltd (China)
· Jingzhou Natural Astaxanthin Inc. (China)
· JX Nippon Oil & Energy Corporation (Japan)
· Katra Phytochem Pvt Ltd (India)
· MBD Industries Limited (Australia)
· MC Biotech Sdn. Bhd. (Brunei)
· Shandong Wefirst Biotechnology Co., Ltd. (China)
· Supreme Health New Zealand Limited (New Zealand)
· Tianjin Norland Biotech Co., Ltd. (China)
· Yunnan Alphy Biotech Co., Ltd. (China)
· Zhejiang Medicine Co., Ltd. (China)
· Zhejiang NHU Co., Ltd. (China)*10. REST OF WORLD*Major Market Players· Algatechnologies Ltd. (Israel)
· Alimtec SA (Chile)
· Andexs Biotechnology SRL (Peru)
· Atacama Bio Natural Products SA (Chile)
· Lycored Ltd. (Israel)
· NextFerm Technologies Ltd (Israel)

For more information about this report visit https://www.researchandmarkets.com/research/qrrspn/global?w=12

CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Food Additive Chemicals Reported by GlobeNewswire 1 hour ago.

ZetaDisplay: Signs a new agreement with Kesko

0
0
ZetaDisplay has entered into a framework agreement with Kesko regarding the delivery of Digital Signage and ESL systems. This agreement will replace the agreement signed 2016 with K-Market, K-Supermarket and K-Citymarket chains and covers now the whole Kesko group.  “We are very pleased to have reached this agreement, which strengthen and broadens our co-operation regarding the Digital Signage and ESL concept delivery with one of the major retail groups in Finland, explains Leif Liljebrunn, CEO ZetaDisplay AB (publ).

ZetaDisplay is in an expansive phase and has positioned itself in the market by being able to show markedly increased sales and improving communication for its clients by means of the company's media platform for Digital Signage.

ZetaDisplay is a leading supplier of Digital Signage to major chains in the retailing and service sectors of the Nordic market. ZetaDisplay has about 140 employees and subsidiaries in Sweden, Denmark, Norway, Estonia, Holland and Finland.

Kesko is a Finnish listed trading sector company. Kesko operates in the grocery trade, the building and technical trade and the car trade. Its divisions and chains act in close cooperation with retailer entrepreneurs and other partners.

Kesko has around 1,600 stores engaged in chain operations in Finland, Sweden, Norway, Estonia, Latvia, Lithuania, Poland and Belarus.

Kesko and K-retailers form the K-Group, whose sales (pro forma) totalled about €13 billion in 2017. The K-Group is the third largest retailer in northern Europe and it employs around 42,000 people.

Kesko's shares are listed on Nasdaq Helsinki. The company's domicile and main premises are in Helsinki.

If you have questions, please contact:

ZetaDisplay AB (publ)
CEO Leif Liljebrunn
Telephone: +46 70 845 80 52
E-mail: leif.liljebrunn@zetadisplay.com

CFO Ola Burmark
Telephone: +46 70 821 57 86
E-mail: ola.burmark@zetadisplay.com

*
*

*About ZetaDisplay*ZetaDisplay (publ) is a leading provider of digitization solutions for the retail and service industry. The company helps retail and service companies become more competitive by providing innovative services and products closing the gap between digital and physical. ZetaDisplay is in a strong growth phase and intends to establish itself globally during the forthcoming years. The company’s headquarter is located in Sweden, with sales offices in Denmark, Norway, Finland, Estonia and the Netherlands. Since December 2017, the share has been traded on Nasdaq Stockholm's main market (“ZETA”). Follow the company on Twitter https://twitter.com/zetadisplaypubl. Website: http://zetadisplay.com/. Reported by GlobeNewswire 1 hour ago.

Sport24.co.za | Ryder Cup worry for Europe after Casey withdrew from BMW

0
0
European Ryder Cup captain Thomas Bjorn will be fretting over one of his wildcard picks after Paul Casey withdrew at the BMW Championship. Reported by News24 1 hour ago.

Government plans to turn UK into an EV tech world leader

0
0
Prime minister announces £106 million boost for developing 'green' vehicles and battery tech

Theresa May has revealed plans to fund projects developing 'green' vehicle technology at the inaugural Zero Emission Vehicle (ZEV) Summit.

The funding injection will include £106 million of government money, with an extra £500m investment from “key industries in this sector”. The prime minister, speaking at ZEV in Birmingham, said that she has set an “ambitious mission” for the country. 

May added: “I want to put the UK at the forefront of the design and manufacturing of zero-emission vehicles, and for all new cars and vans to be, effectively, zero-emission by 2040. Already we are taking significant strides forward. Our electric UK-manufactured cars account for one in five sold in Europe.” 

At least 1000 UK jobs will be created in the plans, which fit in with the government’s previously announced ‘Road to Zero’ strategy. May's speech confirmed that the government intends to provide “over £10m of funding for innovators in ultra-low emission vehicles and hydrogen technology”. 

May also said the measures are intended to “drive the design, use, uptake and infrastructure necessary for cleaner, greener vehicles”. Such developments will be vital in ensuring the UK can meet the standards highlighted in the Paris Climate Change Agreement. 

*£500 million private investment pledged*

The list of companies lined up to invest in projects relating to low-emission technology includes Aston Martin, with its £50m investment in its Welsh ‘centre for electrification’, and powertrain specialist Cummins, set to spend £210m in R&D over the next three years in the UK.

Further firms mentioned include EV Network, a UK-based charging station development company investing around £200m, and Zhuzhou CRRC Times Electric Co, which has chosen Birmingham as its new R&D innovation centre for EVs, rail and renewable. 

Also announced today is the UK’s first independent battery manufacturing facility for the automotive industry, created in a joint venture between Williams Advanced Engineering and Unipart Manufacturing Group. It will open at the start of 2019. 

*Read more*

*Analysis: Is the UK ready for an electrified vehicle future?*

*Hybrid vehicles confirmed as exempt from UK petrol and diesel ban* 

*London Ultra Low Emission Zone to affect 500,000 motorists from 2021*

  Reported by Autocar 1 hour ago.

Global Scleroderma Diagnostics And Therapeutics Market Worth Over USD 3,165.85 Million By 2024: Zion Market Research

0
0
According to the report, global scleroderma diagnostics and therapeutics market was valued at approximately USD 1,607.27 million in 2017 and is expected to generate revenue of around USD 3,165.85 million by end of 2024, growing at a CAGR of around 10.21% between 2018 and 2024.

New York, NY, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled *“Scleroderma Diagnostics and Therapeutics Market by Drug Class (Immunosuppressive Agents, Corticosteroids, Endothelin Receptor Agonists, Calcium Channel Blockers, Chelating Agents, PDE-5 Inhibitors, H2 Blockers, Prostacyclin Analogues, ACE Inhibitors, and Proton Pump Inhibitors), by Indication (Systemic and Localized), and by Diagnostic Test Type (Imaging Techniques, Skin Biopsy, Electrocardiogram and Echocardiogram, Pulmonary Function Tests, and Blood Test): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024”*. According to the report, global scleroderma diagnostics and therapeutics market was valued at approximately USD 1,607.27 million in 2017 and is expected to generate revenue of around USD 3,165.85 million by end of 2024, growing at a CAGR of around 10.21% between 2018 and 2024.

Scleroderma is an autoimmune condition that is characterized by hard and thickened skin along with blood vessel problems. Scleroderma is a connective tissue disease that results in an overactive immune system. This condition can also lead to scarring, pain, and inflammation. Scleroderma, a chronic disease, sometimes leads to scarring on kidneys and lungs. It might cause blood vessels to thicken leading to high blood pressure and tissue damage. This condition is not infectious, cancerous, or contagious. Scleroderma symptoms vary from person to person.

*Browse through 91 Tables & 34 Figures spread over 110 Pages and in-depth TOC on “Global Scleroderma Diagnostics and Therapeutics Market: Industry Type, Size, Share, Trends and Forecast, 2017 - 2024”.*

*Request Free Sample Report of Global Scleroderma Diagnostics And Therapeutics Market Report @* https://www.zionmarketresearch.com/sample/scleroderma-diagnostics-and-therapeutics-market

There are two types of scleroderma: localized and systemic. In localized scleroderma, the condition is limited to the skin and internal organs are not affected. Apart from the skin, localized scleroderma may also affect underlying muscle and tissue. In systemic scleroderma, the condition spreads to visceral organs. The vascular and the immune systems are affected by systemic scleroderma. Blood vessels are also affected leading to spasmodic color changes. This condition is referred to as Raynaud phenomenon.

The diagnosis of scleroderma is very difficult as it resembles a variety of other disorders. The diagnosis of scleroderma is done by a dermatologist, respirologist, orthopaedist, rheumatologist, or a general internist. The diagnosis relies majorly on the physical examination along with a study of medical history. The diagnosis process starts with a discussion with the patient to note down the medical history followed by a physical examination that includes observation of the affected areas. In order to confirm the diagnosis, the doctor might suggest lab tests. The doctor might also suggest for a skin biopsy. If the affected person shows typical symptoms and skin thickening the diagnosis becomes very easy. However, in some cases, the diagnosis takes several months.

*Download Free Report PDF Brochure: *https://www.zionmarketresearch.com/requestbrochure/scleroderma-diagnostics-and-therapeutics-market

The treatment for scleroderma is aimed at the individual features that influence different areas of the body. To prevent kidney failure, elevated blood pressure levels are treated. Angiotensin-converting enzyme (ACE) inhibitor classes of drugs are frequently used to alleviate blood pressure. There is no medicine available to stop the overproduction of collagen. However, the symptoms and complications of scleroderma can be abated by using multiple medicines. Immunosuppressant drugs are used to reduce the symptoms of scleroderma. Various ointments are also used to prevent infection. Physicians also prescribe mild to strong painkillers. Surgical procedures are used as last resort that includes amputation and lung transplants.       
       
Around 300,000 people have scleroderma in the United States. Out of these, one-third people have systemic scleroderma. As scleroderma develops progressively and appears in varied forms, it is not very easy to diagnose. Currently, a cure for scleroderma doesn’t exist as overproduction of collagen cannot be stopped by any medication. It is, however, possible to treat organ system complications for minimizing damage and maintaining functionality.

*Request the Discount on This Report: *https://www.zionmarketresearch.com/requestdiscount/scleroderma-diagnostics-and-therapeutics-market

Rising incidence of scleroderma and increasing frequency of genetic mutations along with severe environmental changes are the major drivers that will boost the growth of scleroderma diagnostics and therapeutics market. Moreover, the rise in disposable income and increasing awareness regarding preventive healthcare is expected to take the market to new heights. Factors such as extensive R&D related to diagnosis and treatment of scleroderma will create opportunities for the market players. Unfavorable drug effects, ironclad government regulations, high costs related to the diagnosis of scleroderma are some of the factors that will restrict the growth of scleroderma diagnostics and therapeutics market.

The global scleroderma diagnostics and therapeutics market have been segmented into drug class, indication, diagnostic test type, and region. The drug class segment has been segmented into immunosuppressive agents, corticosteroids, endothelin receptor agonists, calcium channel blockers, chelating agents, PDE-5 inhibitors, H2 blockers, prostacyclin analogs, ACE inhibitors, and proton pump inhibitors. Based on the indication, scleroderma diagnostics and therapeutics market have been segmented into systemic and localized. Based on diagnostic test type, scleroderma diagnostics and therapeutics market have been segmented into imaging techniques, skin biopsy, electrocardiogram and echocardiogram, pulmonary function tests, and blood test.

Browse the full *"Scleroderma Diagnostics and Therapeutics Market by Drug Class (Immunosuppressive Agents, Corticosteroids, Endothelin Receptor Agonists, Calcium Channel Blockers, Chelating Agents, PDE-5 Inhibitors, H2 Blockers, Prostacyclin Analogues, ACE Inhibitors, and Proton Pump Inhibitors), by Indication (Systemic and Localized), and by Diagnostic Test Type (Imaging Techniques, Skin Biopsy, Electrocardiogram and Echocardiogram, Pulmonary Function Tests, and Blood Test): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024" *report at https://www.zionmarketresearch.com/report/scleroderma-diagnostics-and-therapeutics-market

North America is a well-developed regional market for scleroderma diagnostics and therapeutics and will present rapid growth in the near future. The U.S. has maintained its number one position in the scleroderma diagnostics and therapeutics market by country in North America. The U.S. is expected to grow at maximum CAGR during the forecast timeframe. This growth is majorly due to the rising cases scleroderma along with rise in disposable income. Moreover, ongoing research to find a cure for scleroderma is expected to boost the growth of scleroderma diagnostics and therapeutics market.

Europe will project significant growth in the near future. The growth will be due to rising awareness regarding preventive health care and climate change.

*Inquire more about this report before purchase @* https://www.zionmarketresearch.com/inquiry/scleroderma-diagnostics-and-therapeutics-market

The Asia Pacific region will grow at the maximum rate during the forecast period. China, Japan, and India are expected to drive the growth for scleroderma diagnostics and therapeutics market. Growth in Asia Pacific market is expected to be driven by climate change and rising incidence of genetic mutations.

Some of the key players in the scleroderma diagnostics and therapeutics market include Bayer AG, Allergan, Inc., Active Biotech AB, BioLineRx, Ltd., Digna Biotech, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Vida Therapeutics Inc., Angion Biomedica Corp., Daval International Ltd., Corbus Pharmaceuticals, Inc., and F. Hoffmann-La Roche Ltd., among others.

*Request customized copy of report @ *https://www.zionmarketresearch.com/custom/3321

*This report segments the global scleroderma diagnostics and therapeutics market as follows:*

*Global Scleroderma Diagnostics and Therapeutics Market: By Drug Class*

· Immunosuppressive Agents
· Corticosteroids
· Endothelin Receptor Agonists
· Calcium Channel Blockers
· Chelating Agents
· PDE-5 Inhibitors
· H2 Blockers
· Prostacyclin Analogues
· ACE Inhibitors
· Proton Pump Inhibitors

*Global Scleroderma Diagnostics and Therapeutics Market: By Indication*

· Systemic
· Localized

*Global Scleroderma Diagnostics and Therapeutics Market: By Diagnostic Test Type*

· Imaging Techniques
· Skin Biopsy
· Electrocardiogram and Echocardiogram
· Pulmonary Function Tests
· Blood Test

*Global Scleroderma Diagnostics and Therapeutics Market: By Region*

· North America

· The U.S.

· Europe

· UK
· France
· Germany

· Asia Pacific

· China
· Japan
· India

· Latin America

· Brazil

· The Middle East and Africa

*Related Reports:*

· *Disabled and Elderly Assistive Technology Market: *https://www.zionmarketresearch.com/report/disabled-elderly-assistive-technology-market
· *Stem Cell Therapy Market:* https://www.zionmarketresearch.com/report/stem-cell-therapy-market
· *In Vivo Toxicology Market:* https://www.zionmarketresearch.com/report/in-vivo-toxicology-market
· *Oncology Nutrition Market:* https://www.zionmarketresearch.com/report/oncology-nutrition-market
· *Digital Health Market: *https://www.zionmarketresearch.com/report/digital-health-market

*About Us:*

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

*Follow Us LinkedIn: *https://www.linkedin.com/company/zion-market-research
*Follow Us Twitter: *https://twitter.com/zion_research

*Blog:* http://www.intenseresearch.com | http://www.mrsresearchgroup.com | http://www.marketresearchtrade.com | https://qyresearchgroup.com | http://marketnreports.com | https://zmrnewsjournal.us | http://www.e-marketresearch.com

*Contact Us:*

Joel John
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
*Email:* sales@zionmarketresearch.com

*Website:* https://www.zionmarketresearch.com

* Blog:* http://zmrblog.com Reported by GlobeNewswire 57 minutes ago.

Kärcher North America Inc. Selects Esker to Automate Its Order Management Process with AI-Driven Solution

0
0
With Esker's order management solution, Kärcher expands its document process automation capabilities.

MIDDLETON, Wis. (PRWEB) September 11, 2018

Esker, a worldwide leader in document process automation solutions and pioneer in cloud computing, announced today that it is working with Kärcher North America, the leading manufacturer of commercial, industrial and consumer cleaning equipment in North America, to automate its order management process. Esker’s AI-driven Order Management solution integrates with the company’s existing SAP® system, automating tasks associated with order processing and offering a central platform for all orders and related information.

Kärcher already uses Esker to receive business documents electronically and has decided to expand on Esker’s capabilities by employing cloud-based order management for quicker, more efficient handling of customer orders. The solution will address the following concerns:· Growing order volume. As Kärcher has grown over the years, so has the number of orders it receives. Esker’s solution will allow staff to keep up with changes in volume by eliminating tedious data entry and storing all documents electronically for easy retrieval.
· Priority order handling. Without differentiation of priority orders, the staff had difficulty meeting customer expectations. With Esker, separate queues allow priority orders to be handled quickly and appropriately. The solution dashboard displays the number of orders in each queue, giving staff and managers much-needed information at a glance.
· Low employee productivity. Receiving more than 20,000 orders per month, a team of 22 Customer Service Representatives (CSRs) were responsible for manually entering orders while simultaneously servicing other customer inquiries. Different teams often had to step in to help ensure all orders were entered timely. Now, Esker’s machine-learning technology will expedite order entry, reduce order backlog and free up CSRs to spend time with customers on more value-added services.

“Our order management process was so labor intensive that we couldn’t measure much in terms of performance,” said Amber Tunseth, director of customer care at Kärcher North America. “Esker’s dashboard will bring us greater visibility from start to finish and allow us to monitor operations without physically going through all of the orders.”

About Kärcher North America
Kärcher North America is one of the largest subsidiaries of the Kärcher Group with over 1,000 employees in eight locations (including three manufacturing facilities). In North America, Kärcher produces and distributes products and services under the brands Kärcher, Windsor Kärcher Group, Landa Kärcher Group, Hotsy, Water Maze, Spraymart, Cuda Kärcher Group, WOMA Kärcher Group and Shark Kärcher Group. The company’s solutions serve customers’ cleaning needs in an economical and environmentally-friendly manner.

About Esker
Esker is a worldwide leader in cloud-based document process automation software, helping financial and customer service departments digitally transform their order-to-cash (O2C) and purchase-to-pay (P2P) cycles. Used by more than 6,000 companies worldwide, Esker’s solutions incorporate technologies like artificial intelligence (AI) to drive increased productivity, enhanced visibility, reduced fraud risk, and improved collaboration with customers, suppliers and internally. Esker operates in North America, Latin America, Europe and Asia Pacific with global headquarters in Lyon, France, and U.S. headquarters in Madison, Wisconsin. For more information on Esker and its solutions, visit http://www.esker.com. Follow Esker on Twitter @EskerInc and join the conversation on the Esker blog at blog.esker.com. Reported by PRWeb 59 minutes ago.

Global Smart Mining Market 2017-2023: Evolution of the Smart Mines Around the World and Increasing Expenditure of ICT

0
0
Dublin, Sept. 11, 2018 (GLOBE NEWSWIRE) -- The "Global Smart Mining Market - by Type, Equipment, Component, Software and Solution, Service, Region - Market Size, Demand Forecasts, Company Profiles, Industry Trends and Updates (2017-2023)" report has been added to *ResearchAndMarkets.com's* offering.The Global Smart Mining Market was worth 7.904 Billion USD in 2017 and it is estimated to grow to 16.18 Billion USD by 2023 with a CAGR of 12.69% between 2017 and 2023.

Smart Mining or the connected mining is the use of advanced technology to connect and communicate with the systems involved in mining. This smart mining has the ensuring efficiency and always performs reliable operations. In this IoT and other smart devices are used which gives better operational management.North America is expected to witness a largest Global Functional Printing Market share due to increasing demand for base and precious metals in the region followed by Asia Pacific region and Europe.

The evolution of the smart mines around the world and increasing expenditure of ICT over mining industry are the factors which drives the growth of Global Smart Mining Market.

*Industry Structure and Updates*

In March 2017, two top Smart Mining Companies Gekko Systems and Rockwell Automation signed a Memorandum of Understanding in order to develop software solution which assists mining customers globally.

*Key Topics Covered:*

*1. Research Methodology *

*2. Executive Summary *

*3. Market Overview *

*4. Market Dynamics *

*5. Global Smart Mining Market Segmentation, Forecasts and Trends - by Type *
5.1. Underground Mining
5.2. Surface Mining

*6. Global Smart Mining Market Segmentation, Forecasts and Trends - by Equipment *
6.1. Excavator
6.2. Robotic Truck
6.3. Driller & Braker
6.4. Load Haul Dump
6.5. Others

*7. Global Smart Mining Market Segmentation, Forecasts and Trends - by Component *
7.1. Sensors
7.2. RFID Tags
7.3. Intelligent Systems
7.4. Others

*8. Global Smart Mining Market Segmentation, Forecasts and Trends - by Software and Solution *
8.1. Logistics Software
8.2. Data & Operation Management Software
8.3. Safety & Security Systems
8.4. Connectivity Solutions
8.5. Analytics Solutions
8.6. Remote Management Solutions
8.7. Asset Management Solutions

*9. Global Smart Mining Market Segmentation, Forecasts and Trends - by Service *
9.1. Support & Maintenance
9.2. System Integration
9.3. Consulting Services

*10. Global Smart Mining Market Segmentation, Forecasts and Trends - by Region *

*11. Company Market Share Analysis *

*12. Company Profiles *· Cisco Inc
· Hitachi Construction Machinery Co. Ltd
· SAP SE
· Rockwell Automation
· Joy Global Inc
· Komatsu Ltd
· Symboticware Inc
· ABB Ltd
· Trimble Navigation Limited
· Caterpillar Inc
· Atlas Copco
· Outotec Oyj
· Alcatel-Lucent
· Thingworx
· Hexagon AB
· Intellisense

For more information about this report visit https://www.researchandmarkets.com/research/36gkqv/global_smart?w=12

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Mining Equipment Reported by GlobeNewswire 57 minutes ago.

Global Orphan Drug Pipeline & Regulatory Insight Report 2018

0
0
Dublin, Sept. 11, 2018 (GLOBE NEWSWIRE) -- The "Global Orphan Drug Pipeline & Regulatory Insight 2025" report has been added to *ResearchAndMarkets.com's* offering.*Global Orphan Drug Pipeline & Regulatory Insight 2025 Report Highlights:*

· Global Orphan Drug Market Overview: US$ 260 Billion Opportunity
· Global Orphan Drug market by Segment
· Regulatory Landscape: USA, Europe & Asia
· Orphan Drug Designation & Reimbursement Policy: USA, Europe & Asia
· Global Orphan Drug Clinical Pipeline Insight: 973 Drugs
· Marketed Orphan Drug Clinical Insight: 366 Drugs

Global Orphan Drug Pipeline & Regulatory Insight 2025 report gives comprehensive insight on clinical and non-clinical parameters related to development and commercialization of orphan drug market. As per report findings, there are more than 350 orphan designated drugs commercially available in the market and more than 900 in the clinical pipeline. Most of the orphan drugs in clinical pipeline are in Phase - II trials followed by Phase - III trials. More than 30 new orphan designated drugs are further expected to enter the market in next five years.

The orphan drug segment has emerged as a new growth frontier for pharmaceutical companies faced with issues like patent expiry, competition from generics and biosimilars, exhausting pipelines and stringent regulatory and policy framework. Increasing investment in clinical research and rapid commercialization of orphan drugs has resulted in the paradigm shift in operational strategy of pharmaceutical companies. In past, pharmaceutical companies were more focused on the research and development of essential medicines leading to high competition and low financial margins.

The exponential growth in global orphan drug market is driven by favorable regulatory and policy framework, increasing research and developmental activities, high ROI rates , government incentives for drug developmental, market exclusivity along with strong support from FDA and EU Commission in special protocols. The research and developmental activities for orphan drugs have also received impetus thrust from the pharmaceutical companies efforts to overcome the impact of revenue loss due the patent expiry of blockbuster drugs.

In terms of therapeutic application, oncology has been predominant segment in the global orphan drug market landscape followed neurology, rheumatology, hematology, infectious diseases and others. Currently, more than 200 companies are partnering for research and development of more than 300 orphan designated drugs in oncology segment. Oncology, as a therapeutic area has also transformed from evolution to customized or precision medicine in the pharmaceutical industry. Utilizing biomarkers to develop targeted treatments and therapies is an approach which is being increasingly used in recent years, which also further explains the reasons behind this therapeutic area's majority share of orphan drug approvals.*
*

*Key Topics Covered:**1. Orphan Drugs: Regimens For Rare Diseases*

*2. Drivers of Orphan Drug Commercialization*
2.1 Cost Aspects
2.2 Expiration of Patented Drugs
2.3 Economic & Non-Economic Incentives
2.4 Advantage of Patent & Market Exclusivity
2.5 High Investment in Research & Development

*3. Global Orphan Drug Market Perspectives: Current Market Evaluations*

*4. Global Orphan Drug Market by Segmentation*
4.1 Market by Class Variation
4.2 Market by Therapeutic Application
4.3 Market by Regions

*5. Global Orphan Drug Clinical Pipeline Overview*

*6. Global Orphan Drug Designation Criteria*
6.1 US
6.2 Europe
6.3 Asia & Australia
6.3.1 Japan
6.3.2 Taiwan
6.3.3 South Korea
6.3.4 Australia

*7. Global Orphan Drug Reimbursement Policy*
7.1 US
7.2 Europe
7.3 Asia

*8. FDA Regulation for Clinical Trials Orphan Designated Drugs*
8.1 Content & Format Of A Request For Written Recommendations
8.2 Provision For Granting & Refusing Written Recommendations
8.3 Content And Format Of A Request For Orphan Drug Designation
8.4 Verification Of Orphan Drug Status & Resident Agent For Foreign Sponsor
8.5 Timing Of Requests For Orphan Drug Designation & Designation Of Already Approved Drugs
8.6 Deficiency Letters And Granting Orphan Drug Designation
8.7 Refusal To Grant Orphan Drug Designation
8.8 Amendment & Change In Ownership To Orphan Drug Designation
8.9 Publication & Revocation Of Orphan Drug Designations
8.10 Annual Reports Of Holder Of Orphan Drug Designation
8.11 Scope & FDA Recognition Of Orphan Drug Exclusive Approval
8.12 Protocols for Investigations & Availability of Information

*9. EMA Regulations for Clinical Trials of Orphan Designated Drugs*
9.1 Committee for Orphan Medicinal Products
9.2 How to Apply for Orphan Designation in Europe
9.3 Marketing Authorization & Market Exclusivity
9.4 Transferring An Orphan Designation To Another Sponsor
9.5 Mandatory Submission Of Annual Report On Development
9.6 Incentives For Micro, Small And Medium-Sized Enterprises
9.7 Fee Reductions For Designated Orphan Medicinal Products
9.8 Procedure for Orphan Designation & Incentives for R&D ( Regulation (EC) No 141/2000 )

*10. Asian Regulations for Clinical Trials of Orphan Designated Drugs*
10.1 Taiwan Rare Disease and Orphan Drug Act
10.2 Japan Orphan Drug Regulation

*11. Global Orphan Drug Clinical Pipeline by Company, Indication & Phase*
11.1 Unknown
11.2 Research
11.3 Preclinical
11.4 Clinical
11.5 Phase-I
11.6 Phase-I/II
11.7 Phase-II
11.8 Phase-II/III
11.9 Phase-III
11.10 Preregistration
11.11 Registered

*12. Marketed Global Orphan Drug Clinical Insight by Company & Indication*

*13. Competitive Landscape*
13.1 AOP Orphan
13.2 Agenus
13.3 Alexion
13.4 Bristol Myers Squibb
13.5 Biogen Idec
13.6 Celgene
13.7 Eli Lilly
13.8 Genethon
13.9 Genzyme Corporation
13.10 Glaxosmithkline
13.11 Merck
13.12 Novartis Pharmaceuticals
13.13 Orphan Europe
13.14 Pfizer
13.15 Prosensa
13.16 Rare Disease Therapeutics
13.17 Roche
13.18 Sanofi
13.19 Shire
13.20 Teva PharmaceuticalFor more information about this report visit https://www.researchandmarkets.com/research/wclbqt/global_orphan?w=12

CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery Reported by GlobeNewswire 47 minutes ago.

Google is fighting a big, messy battle over whether expanding the 'right to be forgotten' amounts to censorship

0
0
Google is fighting a big, messy battle over whether expanding the 'right to be forgotten' amounts to censorship· Google is currently fighting a big battle in the EU's top court about whether people's "right to be forgotten" should apply globally to its search engine.
· The right means private citizens in Europe can ask Google and other search engines to scrub certain unflattering results about them.
· France's data protection agency said Google only deletes results from its EU search engines, and that the information is still visible on non-EU domains.
· Google argued on Tuesday that applying the rule globally would impinge on people's right to free expression.

Most people outside Europe don't know much about the digital "right to be forgotten," the idea that private citizens can ask search engines to scrub certain search results about them.

It's a comparatively new idea, but a landmark ruling in 2014 from the European Court of Justice set the initial parameters of how it might apply. That ruling said search engines like Google could be forced to delete results.

That ruling is at the center of a thorny battle between Google and France's data protection agency, CNIL, which is arguing that the right to be forgotten should apply to search engine results globally, not just locally.

According to CNIL's complaint, Google does delete (or "delist") some results from private citizens when requested. But its main bone of contention is that Google isn't delisting the results everywhere — only on Google France and other EU versions of its search engine. Some delisted information, CNIL said, was still visible on non-EU versions of Google.

On Tuesday, Google shot back at a hearing before 15 EU judges and said expanding the right to be forgotten globally would impinge on freedom of speech.

Bloomberg reported that Google's counsel, Patrice Sinosi, described CNIL's proposals as "very much out on a limb" and in "utter variance" with other judgments.

Google isn't alone in arguing that deleting search results might equate to censorship. A number of media organisations including BuzzFeed, Reuters, The New York Times, and various nonprofits have argued the same.

Thomas Hughes, executive director of freedom of expression group Article 19, said: "This case could see the right to be forgotten threatening global free speech.

"European data regulators should not be allowed to decide what Internet users around the world find when they use a search engine. The CJEU must limit the scope of the right to be forgotten in order to protect the right of Internet users around the world to access information online."

*You can read the case documents here.*

*SEE ALSO: Millions of Europeans are asking Google to be 'forgotten' — here's why Americans don't have that option*

Join the conversation about this story »

NOW WATCH: Why TV speakers suck Reported by Business Insider 16 minutes ago.

ArcelorMittal submits revised proposal for the acquisition of Essar Steel

0
0
  

*ArcelorMittal submits revised proposal for the acquisition of Essar Steel*

11 September 2018 - In response to media speculation, ArcelorMittal (the Company) confirms that yesterday, 10 September 2018, it submitted a revised proposal to Essar Steel India Limited’s (ESIL) Committee of Creditors for the acquisition of ESIL. The Company can also confirm that media reports speculating on the financial value of the revised offer are broadly accurate.

The revised offer, which also includes a commitment to pay the entire amount due to the financial creditors of Uttam Galva and KSS Petron, therefore represents unprecedented value to all concerned creditors. Through the revised offer ArcelorMittal demonstrates its serious commitment to India, creditor banks and all ESIL’s stakeholders.

The Company believes ESIL provides it with a compelling opportunity to enter the high-growth Indian steel market and, should it prove successful with the proposed acquisition, ESIL will add significant strategic value to the group’s business.

*ENDS*

*About ArcelorMittal *

ArcelorMittal is the world's leading steel and mining company, with a presence in 60 countries and an industrial footprint in 18 countries. Guided by a philosophy to produce safe, sustainable steel, we are the leading supplier of quality steel in the major global steel markets including automotive, construction, household appliances and packaging, with world-class research and development and outstanding distribution networks.

Through our core values of sustainability, quality and leadership, we operate responsibly with respect to the health, safety and wellbeing of our employees, contractors and the communities in which we operate.

For us, steel is the fabric of life, as it is at the heart of the modern world from railways to cars and washing machines. We are actively researching and producing steel-based technologies and solutions that make many of the products and components people use in their everyday lives more energy efficient.

We are one of the world’s five largest producers of iron ore and metallurgical coal. With a geographically diversified portfolio of iron ore and coal assets, we are strategically positioned to serve our network of steel plants and the external global market. While our steel operations are important customers, our supply to the external market is increasing as we grow.

In 2017, ArcelorMittal had revenues of $68.7 billion and crude steel production of 93.1 million metric tonnes, while own iron ore production reached 57.4 million metric tonnes.

ArcelorMittal is listed on the stock exchanges of New York (MT), Amsterdam (MT), Paris (MT), Luxembourg (MT) and on the Spanish stock exchanges of Barcelona, Bilbao, Madrid and Valencia (MTS).

For more information about ArcelorMittal please visit: http://corporate.arcelormittal.com/   
*Contact information ArcelorMittal Investor Relations*  
   
Europe +44 20 7543 1156
Americas +1 312 899 3985
Retail +44 20 7543 1156
SRI +44 207543 1156
Bonds/Credit +33 171 921 026
   
   
*Contact information ArcelorMittal Corporate Communications*  
 

E-mail:  

press@arcelormittal.com
Phone: +442076297988
   
   
*ArcelorMittal Corporate Communications*  
   
Paul Weigh +44 20 3214 2419
   
   
   
   
    Reported by GlobeNewswire 38 minutes ago.

WORLD SPORTS at 1330 GMT

0
0
TOP STORY:SOC--EUROPEAN ROUNDUPMADRID — Coming off a win over England at Wembley Stadium, Spain hosts World Cup finalist Croatia in the UEFA Nations League. Iceland and Belgium meet in the other League A match in Europe's newest... Reported by New Zealand Herald 26 minutes ago.

Erdogan warns attack on Idlib will send Syrian refugees heading to Europe

0
0
Reported by Telegraph.co.uk 28 minutes ago.
Viewing all 65275 articles
Browse latest View live




Latest Images